Engerix-B®

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline, VBI Vaccines Inc.

Conditions

Hepatitis BMalariaMalaria Vaccines

Phase 2

Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region

CompletedNCT00197028

GlaxoSmithKlineMalaria

Start: 2005-08-23End: 2007-12-27Updated: 2018-08-20

Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants

CompletedNCT00289185

GlaxoSmithKlineMalaria, Malaria Vaccines

Start: 2006-09-27End: 2009-01-15Updated: 2020-10-29

Phase 3

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

CompletedNCT04209400

VBI Vaccines Inc.Hepatitis B

Start: 2014-04-18End: 2015-04-20Updated: 2022-07-25

Related Papers

Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation

Clinical Infectious Diseases2020-10-2310 citations

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region.

2013-01-0831 citations

Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.

2010-11-0432 citations

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.

2008-12-08160 citations

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.

2007-10-18183 citations